| Description | Adecatumumab (MT201) is a whole-person IgG1 monoclonal antibody to human EpCAM. Adecatumumab has potential anticancer activity and can be used to study breast cancer. |
| In vitro | 在人类Adecatumumab和鼠类Adecatumumab的研究中, 观察到在B16/EpCAM 3E3细胞中用Adecatumumab（4 μM；18 h）处理后，绑定动力学活性呈现多样性[2]。Adecatumumab（0.1 ng/mL-0.1 mg/mL；4 h）在天然杀手（NK）细胞中展现出依剂量增减的抗体依赖性细胞介导的细胞毒性（ADCC）活性[2]。 |
| In vivo | 在小鼠B16/EpCAM异种移植瘤模型中，人类adecatumumab与mu-adecatumumab（每鼠300μg；静脉推注；每周3次）均展现出抑制肿瘤生长的效果[2]。人类adecatumumab与mu-adecatumumab（每鼠300μg；静脉推注；单剂量）在血清浓度上显示双指数曲线进展，其特征为0至10小时的早期分布阶段和终末消除阶段[2]。 |
| Synonyms | MT 201 |
| molecular weight | N/A |
| CAS | 503605-66-1 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. 2. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. |